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Abstract
Background: Breast cancer is a disease that afflicts women only 0.5–1% are male breast cancers. Breast 
cancer has several variants and requires a different therapeutic approach, and until now, the therapy has 
not been satisfactory due to the emergence of resistance. Metformin is known to have a cytotoxic effect 
for breast cancer. Aims: This study aimed to analyze the metformin cytotoxic mechanisms covering the 
cell cycle, apoptosis, and expression of p53, bcl-2, and cyclin D1 T47D cells which exposed to metformin 
HCl. Method: The study was conducted in vitro on T47D breast cancer cells which exposed to metformin 
concentrations of 1738.2 µg/mL and 3476.4 µg/mL and doxorubicin concentrations of 0.1 µg/mL and 
0.2 µg/mL for 24 h. Cell cycle testing and apoptosis using the flowcytometry method and expression test of 
p53 protein, bcl-2 and cycline D1 in T47D cells with immunocytochemistry. Data were analyzed by one-way 
ANOVA with Bonferroni’s advanced test. Result:  The results showed that metformin inhibited the G0-G1 
phase of the T47D cell cycle, triggered T47D cell apoptosis, and significantly reduced p53, bcl-2, and cyclin 
D1 protein expression (P <0.05). Conclusion: The conclusion of the study, metformin inhibits T47D cells 
through inhibition of the cell cycle G0-G1 phase, reducing protein expression p53, bcl-2, and cyclin D1.
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Introduction
Cancer is one of the serious world health problems, 
and in 2008, there were 12.7 million new cancer 
cases and 7.6 million died of cancer. The most 
diagnosed cancers worldwide are lung cancer 
(1.6 million, 12.7%), breast cancer (1.38 million, 
10.9%), and colorectal cancer (1.23 million, 
9.7%).[1] The 2012 Globocan statistics showed 
that around 1.7 million women were diagnosed 
with breast cancer with a mortality rate of around 
522 thousand.[2] Clinical breast cancer is classified 
according to morphological characteristics 
including infiltrating ductal carcinoma, infiltrating 
lobular carcinoma, tubular, mucinous, medullary, 
and adenoid cystic carcinoma. Classification based 
on the expression of estrogen receptors and 
progesterone and Her2 oncogene.[2]
The types of breast cancer are diverse according 
to various therapeutic approaches. It reported 
that many kinds of therapy have been carried 
out so far; some of them had problems including 
therapeutic effectiveness that varies among 
individuals or chemotherapy resistance made new 
problems.[3] This study focused on the metformin, 1, 
1-dimetylbiguanide is derived from galegine alkaloid 
or isoamyl guanidine, the active substance of Gallega 
officinalis, also known as Goat’s Rue. It has been 
used since 1958 as a Type 2 diabetes mellitus (DM) 
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drug in the United Kingdom and 1995 at the United 
States and recommended as the first-line therapy 
for all patients newly diagnosed with Type 2 DM 
by the 2014 American Diabetes Association.[4] The 
previous studies showed a reduced risk of cancer in 
Type 2 DM patients using metformin compared to 
patients who did not use metformin such as insulin, 
sulfonylureas, sitagliptin, and pioglitazone.[5,6] In 
practice, metformin works by inhibiting complex 
I respiratory chains in mitochondria[5,7] where 
the mitochondrial respiratory chain functions to 
produce adenosine triphosphate (ATP).[8] Complex 
I barriers in the mitochondrial respiratory chain 
resulted in the decreased cell ATP concentrations 
and increased AMP, then stimulated AMP-kinase.[9] 
Set the activated AMP-kinase would phosphorylate 
various substrates that played a role in cell life.[10]
It found that the research in in vitro has been done 
including among several types of cancer cells such 
as WiDr cells,[11] Hep G-2 cells,[12] MCF-7 cells,[9] 
MDA-MB-231,[13] and MDA-MB-435 all showing 
suppression effects of cancer cell growth. This 
study used T47D cancer cells, ductal type breast 
cancer cells that express p53 proteins that might 
be mutated (missense mutation) at residue 194 
(in the zinc-binding domain, L2).[14] p53, a protein 
encoded in the TP53 gene, a tumor suppressor gene 
(tumor suppressor gene) which acts to block cell 
changes into cancer cells through three inhibiting 
mechanisms, namely quiescence, induction of 
permanent cessation of cells (senescence) or spurring 
programmed cell death (apoptosis), and barriers 
to angiogenesis.[15] Thus, p53 causes antiapoptotic 
effects that occur through its bond with bcl-2, a 
family of antiapoptotic protein from Bcl-2. Then, p53 
activates the proapoptotic bcl-2 protein family; as 
a result, there is an increase in permeability of the 
mitochondrial membrane, cytochrome C is released, 
and finally, apoptosis occurs through activation of 
the caspase.[16] The p53 also has an effect on the cell 
cycle, where p53 acts as a negative regulator protein 
and cyclin kinase groups Cyclin-dependent kinase 
(CDK) as a positive regulator of cell cycle.[16]
It found that p53 mutations in breast cancer cells 
contribute to tumor formation because it increases 
the breast cancer cell defense through the effects of 
cell apoptosis[14,17,18] and also increases resistance to 
chemotherapy[17,18] genomic instability, disruption 
of spindle checkpoint control,[17] and mutant p53 
protein that has shown to be activators a number 
of genes including c-Myc, topoisomerase I, and 
MDR-1.[19]
Early research conducted by Rangkuti et al., 2018, 
showed that metformin had a cytotoxic effect on 
T47D breast cancer cells with IC
50 
1738.2 µg/mL, 
much smaller than the control of doxorubicin with 
IC
50 
0.1 µg/mL.[20] The mechanism of the inhibition of 
T47D cell growth is due to exposure to metformin. 
It requires further investigation of the cells cycle 
and apoptosis along with the proteins that play a 
role in it.
Materials and Methods
Cell line and reagent
This research used the T47D breast cancer cell line 
which was provided by the Faculty of Medicine, 
Gadjah Mada University of Indonesia. Cells are 
cultured in RPMI 1640 media (Sigma, USA) with 
10% fetal bovine serum (Thermo, Chile), under 
standard culture conditions (37°C, 95% humidified 
water, and 5% CO2). Metformin was produced by 
PT. Metformin was produced by PT. Dexa Medica 
Palembang (Indonesia), but Oxoxorubicin was by 
PT. Ferron Parr Pharmaceuticals of Indonesia. This 
study used the anti-p-53 antibodies, anti-bcl-2, and 
anti-cyclin D1 (Sigma, America). The serial dilution 
solution of the sample is prepared immediately 
before the experiment was carried out.
Cell cycle testing and apoptosis
Apoptosis and T47D cell cycle testing were using 
the method of flow cytometry. The number of 
cells needed 5 × 105 cells/well on the 6-well plate, 
incubated for 24 h; the next day, the cell plus the 
metformin solution was reincubated for 24 h. Then, 
the media of each well is inserted in each 15 mL 
cone tube, washed with phosphate-buffered saline 
(PBS) 1 time reenter the same cone. Added 250 µL 
trypsin to each well and then incubated for 3 min. 
After that, plus 1 mL of culture media; then, the 
media was accommodated in the same cone tube. 
Centrifuging at a speed of 600 rpm for 5 min, the 
supernatant was discarded. Added 1 mL PBS, the 
media was transferred to a 1.5 mL microtube; 
it was centrifuged again at a speed of 2000 rpm 
for 3 minutes, after which the supernatant was 
removed. Cell cycle testing and iodide propidium 
were done while apoptosis testing plus Annexin 
V and iodide propidium were made. Then, it was 
measured by means of the FACSCalibur (Becton-
Dickinson) flowsitometer.[21] The cell pellets were 
suspended in 50 μg/ml propidium iodide in the 
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presence of 100 μg/ml RNase and Triton-X solution 
and incubated for 10 min at 37°C in the dark. Cell 
cycle distribution was analyzed using the flow 
cytometry, then analyzed with the Cell Quest 
program.
Immunochemistry
Analysis of protein expression of p-53, Bcl-2, and cyclin 
D1 was using T47D cells grown immunochemistry. 
Before T47D cell is being planted, first put each 
coverslip in a 24-well pitting plate. The cell planted 
at a density of 5 × 104 cells/wells, incubated for 
the last 24 h, then the media discarded. Cell that 
being incubated then added with metformin test 
solution incubated back for 24 h. After incubation, 
the metformin test solution and the culture media 
are removed, washed with PBS 1 time. Cells were 
fixed with cold methanol (Merck) for 10 minutes and 
discarded. After that, coverslip on each of the wells 
is removed and placed on a glass slide, washed with 
PBS 2 times, washed with distilled water, and then 
got dried; add the prediluted blocking serum at room 
temperature for 10 minutes, then discarded. After 
incubation, the monoclonal antibodies p-53/Bcl-2/
cyclin D1 were added to the cells and then incubated 
for 1 hour at room temperature. Coverslip then 
washed with PBS and etched secondary antibody 
(Biotinylated universal secondary antibody) (Star Trek 
Universal HRP Detection Kit, Ref. STUHRP 700L10-KIT, 
Biocare Medical) and incubated for 10 min. The cells 
washed again using PBS and etched with streptavidin 
enzyme horseradish peroxidase (HRP, Star Trek 
Universal Detection Kit, Ref. STUHRP 700L10-KIT, 
Biocare Medical) and incubated for 10 minutes. Cells 
were washed and then added 3,3’-diaminobenzidin 
(DAB) (Star Trek Universal HRP Detection Kit, Ref. 
STUHRP 700L10-KIT, Biocare Medical), incubation 
for 2 min (until the brown color). Cells were washed 
again with PBS and distilled water then with a 
solution Mayer-Hematoxylin (Dako) and incubated 
for 5 minutes, and then cells were washed again using 
distilled water to clean, add 70% ethanol incubation 
for 2 min, wipe, then dropped into a solution of xylol 
and dry. After drying, coverslip placed on a glass slide 
and a few drops of mounting media and covered 
with a cover glass. Cells observation was performed 
using Olympus brand light microscope with ×400.
Results: Metformin Inhibits The G0-G1 
Phase of the T47d Cell Cycle
Previous research showed that the metformin has 
a cytotoxic effect against cancer cells T47D. To find 
its effect, then a test to determine the cell cycle 
bottleneck effect of metformin on cell cycle[20] 
was administered. It was made by the exposure 
to metformin concentrations of 1738.2 mg/mL 
and 3476.4 g/mL for 24 h[20] which showed the 
accumulation of cells in G0-G1 phase, that is, dose 
dependent, whereas exposure to doxorubicin 
concentration of 0.1 mg/mL and 0.2 mg/mL for 
24 h[20] showed barriers G0 phase of the cell cycle at 
the G2-M-G1d [Figure 1 and Table 1].
Table 1: Percentage of accumulation in each 
phase in the T47D cell cycle
Kinds of treatment Cell cycle phase (%)
G0-G1 S G2-M
Control cell 49.20 20.93 30.15
Metformin 1738.2 µg/mL 52.99 22.03 25.36
Metformin 3476.4 µg/Ml 54.48 22.07 23.79
Doxorubicin 0.1 µg/mL 27.90 24.75 47.31
Doxorubicin 0.2 µg/mL 39.97 28.22 31.34
Figure 1: T47D cell cycle histogram in (a) control cell (b) exposure to metformin concentration 
of 1738.2 µG/mL (c) exposure to metformin concentration of 3476.4 µG/mL (d) exposure to 
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Metformin decreases cyclin D1 protein expression 
in T47D breast cancer cell
Cell accumulation in the G0-G1 phase due to 
exposure to metformin is then required to trace 
the protein that plays a role, for that the cyclin D1 
expression is examined G1.
Exposure to metformin concentrations of 1738.2 
µg/mL and 3476.4 µg/mL for 24 h[20] to T47D 
cells showed a decrease in cyclin D1 expression 
compared to controls [Figures 2-4, Table 2].
Based on the ANOVA test obtained P = 0.014 
(P < 0.05), there were significant differences in 
the expression of cyclin D1 in all three groups. 
The results show a significant difference in the 
expression of cyclin D1 in the cell group which was 
exposed to metformin 3476.4 µg/mL (4.40 ± 3.89%) 
with control cells (14.61 ± 2.49%) with P < 0.05.
Figure 2: The expression of cyclin D1 in 
control cells T47D
Description: The black arrow indicates cells 
expressing cyclin D1.
Figure 3: The expression of cyclin D1 in 
control cells T47D cells described metformin 
concentration of 1738.2 mG/mL
Description: The black arrow indicates a cell 
that expresses cyclin D1.
Figure 4: Cyclin expression D1 in T47D cell 
described metformin concentration of 
3476.4 mG/mL
Description: The black arrow indicates a cell 
that expresses cyclin D1.
Metformin has apoptotic ability for T47D breast 
cancer cells
The results of apoptotic testing showed that the 
ability of apoptosis metformin was smaller than 
doxorubicin [Figure 5 and Table 3].
Metformin decreases P53 protein expression T47D 
breast cancer cells
In this step, p53 protein expression testing was 
performed on control cell T47D cells, T47D cells 
were exposed to metformin 1738.2 µg/mL and 
3476.4 µg/mL for 24 h, and T47D cells were exposed 
to doxorubicin 0.1 µg/mL and 0.2 µg/mL for 24 h. 
The expression of p53 protein in cells exposed to 
doxorubicin 0.2 µg/mL is difficult to assess due to 
lysis cells.
Cells that positively express p53 visually appear to 
have a brown/dark cytoplasm, whereas cells that 
do not express p53 are bluish transparent.[22]
Table 2: Analysis of cyclin D1 protein 
expression in T47D cancer cell using ANOVA 
test
No. Treatment Expression of 
cyclin D1 in T47D 
cells
P value







Description: Data were analyzed by one-way ANOVA with 
Bonferroni’s advanced test, * P<0.05 versus control
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Based on the ANOVA test obtained P = 0.028 (P < 0.05), 
there were significant differences in the expression of 
p53 in the Figures 6-9. The results according to Table 4 
show a significant difference in the expression of p53 
in the cell group which was exposed to metformin 
3476.4 µg/mL (6.98 ± 2.74%) with the control cell 
group (14.54 ± 1.60%) with P < 0.05.
Metformin decreases BCL-2 T47D breast cancer 
protein expression
Testing of bcl-2 expression was performed on T47D 
cell control cells, T47D cells which were exposed 
to metformin 1738.2 µg/mL and 3476.4 µg/mL 
for 24 h and T47D cells exposed to doxorubicin 
0.1 µg/mL and 0.2 µg/mL for 24 h. Expression of 
bcl-2 in cells exposed to doxorubicin 0.2 µg/mL is 
difficult to assess due to lysis cells.
Visually positive cells expressing bcl-2 appear to 
have a brown/dark cytoplasm, while cells that do 
not express bcl-2 are colored bluish transparent.
Based on the ANOVA test, it obtained P = 0.000 
(P < 0.05), there were significant differences in 
the expression of bcl-2 in the Figures 10-13. The 
corresponding results in Table 5 show a significant 
difference in the expression of bcl-2 in the cell group 
exposed to metformin 1738.2 µg/mL (5.46 ± 1.19%) 
and doxorubicin 0.1 µg/mL (7.4 ± 2.00%) with the 
control cell group (14.54 ± 1.60%) with p value < 0.01, 
and in the metformin group, 3476.4 µg/mL (2.84 ± 
1.16%) significantly different from the control cell 
(14.54 ± 1.60%) with a value of P < 0.001.
Discussion
It was found that in the previous studies showed 
that metformin had cytotoxic activity against T47D 
cells with IC
50 
1738.1875 ± 141.63 µg/mL.[20] The 
toxicity of metformin to cells T47D was based on 
the mechanism of metformin inhibiting complex I 
respiratory, chains in mitochondria. It ended up 
stimulating various substrates which caused various 
effects in the form of activation of glycolysis. Thus, 
Table 3: Results of T47D cell apoptosis tests
Treatment R1 (%) R2 (%) R3 (%) R4 (%)
Control cell 96.45 0.64 1.73 1.20
Metformin 1738.2 µg/mL 94.67 1.28 2.44 1.42
Metformin 3476.4 µg/mL 91.31 1.86 3.92 2.90
Doxorubicin 0.1 µg/mL 53.61 7.99 28.41 10.14
Doxorubicin 0.2 µg/mL 31.71 11.19 31.25 26.20
Description: R1=Living cell; R2=Cells undergo initial apoptosis; R3=Cells undergo final apoptosis; R4=Cells undergo necrosis
Figure 5: T47D cell apoptosis test in (a) control cells (b) exposure to metformin concentration 
of 1738.2 µG/mL (c) exposure to metformin concentration of 3476.4 µG/mL (d) exposure to 
doxorubicin concentration of 0.1 µG/mL (e) exposure to doxorubicin concentration of 0.2 µG/mL
Description: R1=Living cell; R2=cells undergo initial apoptosis; R3=cells undergo final 
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the inhibition of anabolic pathways in inhibiting 
fatty acid synthesis, cholesterol, synthesis of 
ribosomal RNA, resistance to cycles cells through 
AMPK phosphorylation to p-53 which causes an 
increase in transcription of p-21 a CDK inhibitor that 
plays a role in the cell cycle, and has an effect on the 
occurrence of apoptosis.[5,7,8,10]
The mechanism of cytotoxic metformin had been 
tested through the cell cycle and apoptosis. It was 
a cell cycle of proliferation process that mediated 
the growth and development of living things, had 
two main phases, namely the S phase (synthesis) 
and the M phase (mitosis). Phase S was the phase 
of chromosomal DNA replication in cells while 
in Phase M, there is a separation of two sets of 
chromosomal DNA into two cells.[23] In addition, 
there were phases that limit the two main phases 
called Gap: G1 (Gap-1) before the Phase S and after 
the S phase is called G2 (Gap-2). In the G1 phase, the 
cell prepares for DNA synthesis. That phase was the 
initial phase of cell cycle progression regulated by 
extracellular factors such as mitogens and adhesion 
molecules. That phase marker was the expression 
and synthesis of protein as preparation for entering 
the S phase. In the G2 phase, the cell carried out 
further synthesis which sufficient for the cleavage 
process so that the cell was ready to do division in 
the M phase.[24]
This study displayed metformin, leading to cell cycle 
arrest in the G0-G1 phase, that was in accordance 
with the results of the Qu and Cai study.[12,25] G1 
(Gap-1) is a cell preparation phase for DNA synthesis, 
and this phase would be exceeded if cell requirements 
such as nutrition, cell size, and growth factors have 
been fulfilled. Metformin working by inhibiting the 
Table 4: Analysis of P53 protein expression in 
T47D cancer cells using ANOVA test
No Treatment Expression of 
p53 to T47D 
cell (mean ± SD %)
P value










Description: Data were analyzed by one-way ANOVA with 
Bonferroni’s advanced test, * P<0.05 versus control
Table 5: Analysis of bcl-2 protein expression 
in T47D cells using ANOVA test
No. Treatment bcl-2 Expression 
toT47D cell
P value










Description: Data were analyzed by one-way ANOVA with 
Bonferroni’s advanced test, * P<0.05 versus control, ** P<0.01 
versus control, *** P< 0.001 versus control
Figure 6: Expression of P53 proteins in T47D 
control cells
Description: Black arrows indicate cells 
expressing p53.
Figure 7: Expression of P53 in T47D cells 
exposed to metformin concentration of 
1738.2 µG/mL
Description: Black arrows indicate cells 
expressing p53.
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mitochondrial respiratory chain I complex with the 
consequent inhibition of ATP formation resulting in 
AMPK activation which caused barriers to protein 
synthesis, lipids, and ribosomal RNA which were 
needed by cells to live and develop.[12,26] It explained 
that the occurrence of cell growth barriers through 
cell cycle arrest in the G0-G1 phase. The extension 
of the G0-G1 phase also occurred in MCF-7 cells 
exposed to a concentration of 2.5, 5, 10, and 20 
mM and increasingly elongated in the next 2 and 
3 days of metformin exposure.[9] Different from 
doxorubicin which also works in the G2-M phase, 
cytotoxic activity of Doxorubicin through inhibition 
of topoisomerase II, DNA intercalation, membrane 
cell binding and the formation of semiquinone free 
radicals and oxygen free radicals.[27]
Doxorubicin is one of the anthracycline anti-
breast cancer drugs currently used in combination 
regimens and for other types of cancer such as 
leukemia.[28] Doxorubicin was used as a positive 
control in this study, because the drug was still used, 
and it showed an anti-cancer effect on T47D cells.[29] 
Doxorubicin working specifically in the S phase that 
was related to its mechanism of action to inhibit 
DNA and RNA synthesis, intercalation between 
base pairs and interact with topoisomerase II.[30]
Metformin exposure slightly increased T47D cell 
apoptosis compared to the effect of doxorubicin 
apoptosis. Previous metformin research on T47D 
Figure 8: Expression of P53 in T47D cells 
exposed to metformin concentration of 
3476.4 µG/mL
Description: Black arrows indicate cells 
expressing p53.
Figure 9: Expression of P53 in T47D cells 
exposed to doxorubicin concentration of 
0.1 µG/mL
Description: Black arrows indicate cells 
expressing p53.
Figure 10: Expression of bcl-2 Proteins in 
T47D control cells
 Description: Black arrows indicate cells 
expressing bcl-2.
Figure 11: Expression of bcl-2 in T47D cells 
exposed to metformin concentration of 
1738.2 µG/mL
 Description: Black arrows indicate cells 
expressing bcl-2.
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cells indicated that the metformin inhibits T47D cell 
growth through activation of AMPK and histone H2B 
inhibition monoubiquitination[31] and metformin 
caused apoptosis in T47D cells and increased 
expression of caspase 8 and 9.[32] The study used 
the serial concentrations of 5, 10, and 50 µM and 
evaluated for 24, 48, and 72 hours, the maximum 
effect occurred after exposure to metformin 50 µM 
for 72 h.[32]
Other studies on MDA-MB-231 and MDA-MB-435 
cell types of breast cancer cells using serial 
concentration of 1.25, 2.5, 5, 10, and 20 mmol/l 
for 24, 48, and 72 h. Cells undergoing apoptosis 
increased from 7% with exposure to 5% metformin 
to 39.6% with exposure to 20 mM metformin for 24 
hours, cytotoxic effects and apoptosis of metformin 
through the intrinsic mitochondria-mediated 
apoptosis pathway.[33]
It noted that p53 was a tumor suppressor that 
maintained gene stability, played a role in the cell 
cycle, apoptosis, senescence, and differentiation. 
The mutation of p53 will cause a loss of the function 
of maintaining genome stability, even triggering 
cancer[14,34,35] Decreasing expression of p53 protein 
that undergoes mutations in T47D cells will reduce 
the growth of cancer cells; this is in line with the 
effect on the extension of the G0-G1 phase in the 
cell cycle; there are barriers to cell growth. P53 
acts as a mediator for cell cycle arrest.[36] This is 
consistent with research on T47D cells and MDA-
MB-468 cells by silencing endogenous p53 through 
lentiviral shRNA which shows massive cell death 
through apoptosis with nuclear blebbing, PARP-1 
cleavage but does not occur in MCF-7 or MCF-10A 
with normal p53 conditions.[14]
It is also stated that mutant p53 is an activator of 
a number of genes such as c-Myc, topoisomerase 
I, and MDR-1[19] which cause genome instability 
and the occurrence of spindle checkpoint control 
interference.[17] This study observed three protein 
expressions, namely p53, bcl-2, and cyclin D1. The 
results showed a decrease in expression of p53, bcl-
2, and cyclin D1 proteins. Decreasing the expression 
of p53 in T47D cells which in a state of mutation 
explains the effects of metformin and doxorubicin 
inhibiting T47D cell growth. Lim et al. in their study 
stated that in cells T47D and MDA-MB-468 (both 
cells experienced a p53 mutation), after p53 was 
silenced with lentiviral shRNA, there was no change 
in the expression levels of pro-apoptotic proteins 
that were directly regulated p53 such as PUMA and 
NOXA.[14] The connection of p53 with bcl2 could be 
seen from the following figure, which explained 
that the regulation of p53 could occur directly by 
binding to bcl2 or through PUMA, NOXA, and Bim 
[Figure 14].[37]
Decreasing bcl2 expression in T47D cells exposed 
to metformin and doxorubicin could explain the 
increase in cells undergoing apoptosis in this 
study. It would be stated that a decrease in bcl2 
expression is one of the mechanisms of apoptosis 
that occurred in T47D cells exposed to metformin 
and doxorubicin.
Replication and division of cell DNA occurs through 
the cell cycle, where the cell cycle was a sequence 
of sequences which included G1 (pre-synthesis), 
Figure 12: Expression of bcl-2 in T47D cells 
exposed to metformin concentration of 
3476.4 µG/mL
Description: Black arrows indicate cells 
expressing bcl-2.
Figure 13: Expression of bcl-2 in T47D cells 
exposed to doxorubicin concentration of 
0.1 µG/mL
Description: Black arrows indicate cells 
expressing bcl-2.
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S (DNA synthesis), G2 (premitotic), and M (mitotic) 
phases. Each phase of the cell cycle will occur if the 
previous cell cycle is complete and will stop if there 
is an essential deficiency of gene function. Each 
phase of the cell cycle will be regulated by the cyclin 
and the type of cyclin that regulates differently for 
each phase.[38]
In the cell cycle occurs when critical in the form of 
checking (checkpoint) in several places including the 
phase G1-S and G2-M. For checkpoints in Phase G1-S 
are regulated by cyclin and CKI inhibitors including 
cyclin D1, cyclin E, p21, and p27. Overexpression of 
cyclin D1 and cyclin E supports the development of 
cancer.[39,40] There was a decrease in the expression 
of D1 cyclin between control T47D cells and T47D 
cells exposed to metformin. Decreasing cyclin D1 
expression can explain the occurrence of arrest in 
the phase cell cycle G0-G1 and in accordance with 
the study of Cai et al. on HepG2 cells.[12]
Conclusions
Conclusions of this experimental research are as 
follows:
1. The results of research conducted on the 
metformin in T47D cells; it found the effect of 
metformin on small cell cycle barriers, inhibits 
G0-G phase. Metformin has a smaller effect in 
stimulating T47D breast cancer cell apoptosis 
than that of doxorubicin.
2. Metformin was able to reduce the expression 
of p53, bcl-2, and cyclin D1 in T47D breast 
cancer cells compared to control cells.
3. As a single drug, metformin could effectively 
destroy breast cancer because it only makes 
a small quantity to halt the cancer growth. It 
needs to combine metformin with other drugs.
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